Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen research firms that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12-month price target […]
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) insider James C. Hamilton sold 32,143 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $35.18, for a total value of $1,130,790.74. Following the sale, the insider now owns 218,791 shares of the company’s stock, […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) COO Patrick O’brien sold 8,749 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $32.28, for a total transaction of $282,417.72. Following the sale, the chief operating officer now owns 403,826 shares of the company’s […]
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have received an average recommendation of “Moderate Buy” from the fifteen analysts that are covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month target price […]